Chargement en cours...
Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
BACKGROUND: Due to the increasing number of trials with immune checkpoint inhibitors (ICIs) in the first‐line therapy of non‐small cell lung cancer (NSCLC) patients, we performed a systematic review and meta‐analyses to investigate the difference between anti PD‐1 and PD‐L1 antibodies, used alone or...
Enregistré dans:
| Publié dans: | Thorac Cancer |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley & Sons Australia, Ltd
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8017262/ https://ncbi.nlm.nih.gov/pubmed/33586297 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13867 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|